Lexaria Bioscience Long Term Debt

Lexaria Bioscience (LEXX) currently reports a long-term debt of $54K as of May 2026. That compares with $87K in the prior-year period — down 38.1% year over year. Use the charts on this page to explore Lexaria Bioscience's long-term debt history and peer comparisons.

Lexaria Bioscience's long-term debt decreased from $87K to $54K — a 38.1% year-over-year decrease (period ending May 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lexaria Bioscience reported $54K in long-term debt as of May 2026. That compares with $87K in the prior-year period — down 38.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $54K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lexaria Bioscience, and consider following LEXX for alerts when major investors trade the stock.

Lexaria Bioscience is classified in the Healthcare sector. On long-term debt, it currently shows $54K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LEXX with unrelated industries.